Supira Medical, Inc., A Shifamed Portfolio Company, Receives Fda Breakthrough Device Designation As The Company Closed $40M In Series D Financing
Supira Medical, Inc., A Shifamed Portfolio Company, Receives Fda Breakthrough Device Designation As The Company Closed $40M In Series D Financing
11/21/23, 1:02 PM
Location
campbellIndustry
health care
Investors
Unorthodox Ventures, Pa Med Tech Vc Fund, Amed Ventures, 415 Capital, The Capital Partnership, Cormorant Asset Management, Supira Medical, Inc.
Supira Medical, Inc., a Shifamed portfolio company, announced today that it has received U.S. Food and Drug Administration (FDA) breakthrough device designation for its Supira System, a next-generation percutaneous ventricular assist device (pVAD). This approval comes as the company closed $40M in Series D financing and prepares to initiate its U.S. clinical program
Company Info
Location
590 division street
campbell, california, united states
Additional Info
Supira Medical, a privately held portfolio company of Shifamed, is focused on development of a next generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. To learn more about Supira Medical, please visit www.supiramedical.com.